SBWire

GlobalData's clinical trial report, "Gastroesophageal (GE) Junction Carcinomas Global Clinical Trials Review, H1, 2014" provides data on the Gastroesophageal (GE) Junction Carcinomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastroesophageal (GE) Junction Carcinomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Gastroesophageal (GE) Junction Carcinomas. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Pulmonary Hypertension - Pipeline Review, H1 2014', provides an overview of the Pulmonary Hypertension's therapeutic pipeline.

Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H1 2014', provides an overview of the Nasopharyngeal Cancer's therapeutic pipeline.

Global Markets Direct's, 'Ranbaxy Laboratories Limited - Product Pipeline Review - 2014', provides an overview of the Ranbaxy Laboratories Limited's pharmaceutical research and development focus.

Global Markets Direct's, 'Peanut Allergy - Pipeline Review, H1 2014', provides an overview of the Peanut Allergy's therapeutic pipeline.

Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H1 2014', provides an overview of the Non-Hodgkin Lymphoma's therapeutic pipeline.

Global Markets Direct's, 'Pluristem Therapeutics Inc. - Product Pipeline Review - 2014', provides an overview of the Pluristem Therapeutics Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014" provides data on the Hormone-Sensitive Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone-Sensitive Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone-Sensitive Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Iroko Pharmaceuticals, LLC - Product Pipeline Review - 2014', provides an overview of the Iroko Pharmaceuticals, LLC's pharmaceutical research and development focus.

CEL-SCI Corporation today announced that the Henry Ford Health System in Detroit, Michigan is the latest U.S. clinical center to join the Company's Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection). CEL-SCI is currently expanding and accelerating patient enrollment in its trial. The Company expects to rapidly expand the number of clinical sites active in the U.S. As the world's largest Phase III trial for head and neck cancer, CEL-SCI's study is already active in dozens of clinical centers in 12 countries and is expected to expand to a total of 20 countries by the end of 2015.

Global Markets Direct's, 'Myocardial Ischemia - Pipeline Review, H1 2014', provides an overview of the Myocardial Ischemia's therapeutic pipeline.

Global Markets Direct's, 'IPCA Laboratories Limited - Product Pipeline Review - 2014', provides an overview of the IPCA Laboratories Limited's pharmaceutical research and development focus.

Description There are hundreds of millions of males suffering from sexual dysfunction in the world, of which over 50 million are in China. Statistics indicates that more than 60% of males aged above 35 in China have sexual dysfunction of different degrees. About 50% of the causes of erectile dysfunction are organic, and 30% are psychological while 20% of them are organic and psychological at the same time. Erectile dysfunction can have severe psychological consequences as it can be tied to relationship difficulties and masculine self-image generally. Consequently many pharmaceutical enterprises are very concerned about male sexual dysfunction drug market.

Global Markets Direct's, 'Hemophilia A - Pipeline Review, H1 2014', provides an overview of the Hemophilia A's therapeutic pipeline.

Global Markets Direct's, 'Drug Addiction - Pipeline Review, H1 2014', provides an overview of the Drug Addiction's therapeutic pipeline.

Global Markets Direct's, 'Measles - Pipeline Review, H1 2014', provides an overview of the Measles's therapeutic pipeline.

Ankylosing spondylitis is a systemic, chronic, and progressive inflammatory arthritis in the family of seronegativespondyloarthritis, and is one of the most common rheumatic conditions throughout the world. Ankylosing spondylitis primarily affects the spine and sacroiliac joints, with involvement with other joints in the shoulders, hips, and knees. It can progress into severe inflammation that fuses the spine, leading to permanent painful stiffness of the back. Although treatment helps in relieving pain and stiffness and keeps the spine flexible, the disease is irreversible and people with the disorder have to cope with symptoms throughout their lives. Global prevalence of the disease ranges from 0.01%-1.40%, with higher prevalence in western European Caucasian populations. The epidemiology of ankylosing spondylitis follows a specific geographic distribution mirroring the global variation in prevalence of the HLA-B27 risk allele.

Description According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 20-79 in the world was 8.3% in 2013 with more than 380 million patients worldwide.

GlobalData's clinical trial report, "Neuroblastoma Global Clinical Trials Review, H1, 2014" provides data on the Neuroblastoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroblastoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroblastoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The Age Management Medicine Group has announced the date and location for its upcoming spring conference. The 16th Clinical Applications for Age Management Medicine will take place in Orlando, Florida from April 24-27, 2014.

GlobalData's clinical trial report, "Chemotherapy Induced Pain Global Clinical Trials Review, H1, 2014" provides data on the Chemotherapy Induced Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chemotherapy Induced Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chemotherapy Induced Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis. According to the World Health Organization, an estimated 400 million people worldwide were affected with allergic rhinitis during 1996-2006.

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

GBI Research, has released the pharma report, "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape". The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales.